Pfizer announced that the Centers for Medicare and Medicaid Services (CMS) will cover the cost of the company’s biosimilar Inflectra (infliximab-dyyb) for Medicare enrollees as a Part B-covered drug. Inflectra was approved by the FDA in April 2016 as a biosimilar to Janssen Biotech’s Remicade (infliximab) for reducing signs and symptoms in patients with rheumatoid arthritis, adult and pediatric Crohn’s disease, adult ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis.
The CMS reimbursement price, which took effect January 1, 2017, is a 15% discount to the Wholesale Acquisition Cost (WAC) of Remicade. The WAC does not include discounts to payers, providers, distributors, and other purchasing organizations.
Inflectra is the first biosimilar monoclonal antibody, and the second biosimilar, to become available in the United States. The FDA’s approval of Inflectra as a biosimilar to Remicade did not include interchangeability with the reference drug; pharmacists cannot substitute Inflectra for Remicade without a physician’s instructions.
Pfizer announced the launch of the Pfizer enCompass program, a reimbursement service and patient support program offering coding and reimbursement support for providers, co-pay assistance to eligible patients who have commercial insurance that covers Inflectra, and financial assistance for eligible uninsured and underinsured patients.
Pfizer also announced the availability of pricing for 340B hospitals, a drug pricing program for eligible healthcare organizations that serve as safety net providers, including Medicare/Medicaid Disproportionate Share Hospitals, children’s hospitals, Ryan White clinics, and State AIDS Drug Assistance Programs.
Inflectra began shipping to wholesalers in late November 2016, and can now be ordered from wholesalers across the country.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.